b
r
c
idiopath
pneumonia
syndrom
ip
noninfecti
pulmonari
complic
hematopoiet
cell
transplant
hct
difficult
diagnos
patient
ip
evalu
candid
protein
plasma
sampl
day
posthct
onset
ip
identifi
potenti
diagnost
prognost
biomark
ip
sampl
similar
time
hct
recipi
without
document
infect
hct
recipi
respiratori
viral
pneumonia
serv
control
multivari
model
combin
odd
ratio
p
p
best
panel
distinguish
ip
diagnosi
unaffect
control
wherea
tumor
necrosi
factor
receptor
p
best
marker
compar
patient
ip
viral
pneumonia
area
curv
receiv
oper
characterist
roc
curv
discrimin
ip
unaffect
control
day
posthct
use
estim
sensit
specif
valu
cutoff
determin
roc
analysi
cutoff
level
ngml
pgml
pg
ml
calcul
posit
predict
valu
ppv
rang
estim
popul
preval
valu
ip
among
marker
show
highest
ppv
ip
occurr
base
assum
preval
posit
test
increas
likelihood
ip
conclud
prospect
valid
studi
warrant
determin
whether
plasma
biomark
panel
aid
noninvas
diagnosi
prognosi
ip
idiopath
pneumonia
syndrom
ip
noninfecti
pulmonari
complic
diffus
lung
injuri
hematopoiet
cell
transplant
hct
ip
develop
hct
recipi
accord
recent
studi
mortal
rate
day
ip
high
current
diagnost
criteria
ip
widespread
alveolar
injuri
symptom
sign
pneumonia
activ
lower
respiratori
tract
infect
fact
previou
studi
show
approxim
onehalf
patient
previous
diagnos
ip
viral
pathogen
detect
bronchoalveolar
lavag
bal
sampl
suggest
distinguish
viral
pneumonia
ip
difficult
use
clinic
criteria
although
evalu
bal
sampl
necessari
diagnos
ip
signific
detect
viral
pathogen
pathogen
pneumonia
especi
low
viral
load
necessarili
clear
bronchoscop
evalu
occasion
infeas
due
patient
condit
therefor
noninvas
blood
test
could
aid
ip
diagnosi
assay
accur
identifi
patient
onset
clinic
diseas
prognosi
assay
categor
patient
degre
risk
diseas
occurr
requir
mortal
ip
remain
high
current
standard
treatment
ip
highdos
corticosteroid
although
receptor
inhibitor
promis
drug
yet
establish
treatment
ip
consid
high
mortal
rate
identif
ip
case
earli
phase
ip
potenti
preemptiv
intervent
might
critic
plasma
biomark
may
use
tool
support
diseas
diagnosi
perform
risk
stratif
onset
clinic
sign
predict
outcom
simplic
sampl
biomark
ip
identifi
far
base
previou
report
tumor
necrosi
factor
receptor
candid
biomark
ip
elev
level
bal
sampl
patient
ip
stimul
also
may
candid
consid
elev
acut
lung
injuri
import
biomark
graftversushost
diseas
gvhd
three
proteinslymphocyt
vessel
endotheli
receptor
lyve
endotheli
protein
c
receptor
epcr
herp
viru
entri
mediat
hvem
identifi
potenti
candid
base
separ
proteom
analysi
unpublish
data
aim
present
studi
examin
use
ad
candid
biomark
diagnosi
prognosi
ip
well
compar
profil
viral
pneumonia
among
patient
underw
hct
fred
hutchinson
cancer
research
center
fred
hutch
identifi
patient
ip
occur
within
day
posthct
base
radiograph
find
exclus
occult
viru
fungu
infect
multiplex
pcr
assay
aspergillu
galactomannan
assay
use
frozen
bal
serum
sampl
report
recent
routin
perform
convent
cultur
shell
viral
cultur
direct
fluoresc
antibodi
test
detect
pathogen
use
bal
sampl
patient
viral
pneumonia
due
parainfluenza
viru
piv
human
rhinoviru
hrv
document
bal
sampl
obtain
within
day
posthct
without
copathogen
select
compar
cohort
transplant
recipi
requir
bronchoscop
examin
grow
bacteri
fungal
blood
cultur
within
day
posthct
consid
unaffect
control
patient
demograph
data
transplant
inform
retriev
fred
hutch
databas
studi
approv
institut
review
board
indiana
univers
fred
hutch
cryopreserv
plasma
sampl
day
posthct
within
week
day
onset
event
analyz
onset
sampl
unaffect
control
sampl
closest
day
median
day
onset
patient
ip
select
candid
protein
base
literatur
unpublish
preliminari
data
lyve
epcr
hvem
elisa
kit
purchas
r
system
minneapoli
mn
sequenti
elisa
workflow
use
describ
previous
logist
regress
model
use
evalu
associ
analyt
hct
recipi
ip
versu
unaffect
control
versu
viral
pneumonia
analyt
concentr
univari
model
fit
use
analyt
adjust
model
analyt
construct
stepwis
fashion
ad
demograph
clinic
variabl
model
analyt
retain
variabl
model
inclus
modifi
associ
analyt
outcom
multianalyt
model
develop
determin
whether
combin
protein
improv
discrimin
patient
ip
control
cohort
analyt
ad
model
stepwis
fashion
select
model
lowest
akaik
inform
criterion
valu
area
curv
auc
receiv
oper
characterist
roc
curv
evalu
analyt
assess
abil
discrimin
patient
ip
control
viral
pneumonia
predict
valu
calcul
use
sensit
specif
cutoff
point
closest
top
left
corner
roc
plane
assum
rang
preval
valu
ip
weight
version
kaplanmei
surviv
curv
estim
highversu
lowcytokin
subgroup
logrank
test
evalu
p
valu
proport
subject
ip
far
higher
combin
cohort
would
expect
typic
hct
popul
individu
weight
subject
ip
repres
plausibl
preval
ip
surviv
analysi
among
patient
ip
cox
regress
use
assess
associ
analyt
onset
valu
day
postinfect
surviv
given
limit
number
subject
model
adjust
clinic
demograph
featur
whose
inclus
effect
greatest
chang
least
analyt
associ
outcom
p
valu
consid
statist
signific
statist
analys
perform
use
r
version
evalu
patient
ip
cryopreserv
plasma
sampl
compar
cohort
includ
unaffect
patient
without
bronchoscop
examin
document
infect
patient
piv
hrv
infect
occur
within
day
posthct
characterist
cohort
present
tabl
median
onset
hct
ip
day
viral
pneumonia
case
hct
recipi
unaffect
control
includ
recent
hct
recipi
peripher
blood
stem
cell
cell
sourc
reducedintens
condit
use
often
patient
ip
viral
pneumonia
unaffect
control
clinic
present
gener
similar
patient
ip
viral
pneumonia
among
patient
ip
receiv
corticosteroid
onset
ip
wherea
patient
receiv
corticosteroid
time
day
sampl
collect
concentr
candid
protein
select
base
literatur
unpublish
preliminari
data
epcr
hvem
measur
ip
onset
day
posthct
shown
supplementari
figur
group
concentr
onset
show
trend
toward
increas
median
valu
across
group
unaffect
control
viral
pneumonia
ip
cohort
concentr
day
posthct
gener
onset
ip
case
measur
within
day
follow
diagnosi
show
similar
trend
univari
logist
regress
model
use
predict
ip
versu
unaffect
control
versu
patient
viral
pneumonia
base
biomark
sampl
time
onset
tabl
patient
ip
significantli
elev
hvem
compar
unaffect
control
analyt
except
elev
compar
patient
viral
pneumonia
significantli
increas
day
posthct
patient
eventu
develop
ip
compar
unaffect
control
significantli
elev
ip
day
compar
patient
viral
pneumonia
evalu
whether
biomark
could
improv
prognost
abil
ip
occurr
clinic
criteria
combin
multipl
analyt
analyz
best
combin
comparison
ip
control
onset
day
posthct
tabl
marker
enhanc
abil
distinguish
ip
viral
infect
onset
clinic
sign
analyz
analyt
multivari
model
also
includ
clinic
factor
prove
import
model
figur
supplement
tabl
adjust
variabl
includ
model
shown
figur
onset
ip
hvem
odd
ratio
p
p
p
distinguish
patient
ip
unaffect
control
p
major
protein
could
discrimin
ip
viral
pneumonia
prognosi
day
posthct
p
p
best
discrimin
patient
ip
unaffect
control
wherea
signific
marker
discrimin
ip
viral
pneumonia
time
point
next
produc
roc
curv
biomark
without
adjust
clinic
factor
obtain
threshold
optim
sensit
specif
ip
figur
compar
patient
ip
control
provid
highest
auc
follow
onset
figur
cutoff
valu
identifi
top
left
point
roc
curv
best
balanc
trueposit
rate
falseposit
rate
identifi
ngml
pgml
pgml
day
posthct
auc
valu
lower
rel
high
auc
cutoff
valu
defin
top
left
point
curv
ngml
pgml
pgml
figur
distinguish
ip
viral
pneumonia
onset
sampl
top
left
cutoff
pg
ml
top
left
cutoff
pgml
show
highest
auc
valu
although
rel
low
analyt
figur
togeth
provid
best
model
fit
comparison
patient
ip
control
tabl
calcul
roc
curv
base
multipl
cytokin
model
figur
auc
onset
day
posthct
respect
similar
valu
provid
alon
figur
b
posit
ppv
patient
ip
compar
unaffect
control
highest
follow
figur
instanc
assum
preval
ip
among
hct
recipi
patient
valu
ngml
measur
onset
symptom
chanc
ip
diagnosi
increas
priori
chanc
identifi
ip
case
measur
day
posthct
patient
valu
ng
ml
chanc
develop
ip
near
futur
approxim
higher
assum
preval
ip
expect
view
low
preval
diseas
npv
high
next
evalu
whether
biomark
relat
occurr
ip
provid
reason
predict
surviv
proport
patient
ip
cohort
much
higher
would
expect
combin
popul
downweight
ip
case
make
contribut
analysi
repres
preval
dichotom
patient
high
low
biomark
group
use
top
left
cutoff
valu
roc
curv
day
posthct
calcul
surviv
curv
group
defin
high
versu
low
biomark
level
hypothet
popul
high
p
p
level
day
posthct
significantli
associ
higher
mortal
assum
preval
ip
figur
next
evalu
prognost
valu
biomark
mortal
ip
among
patient
ip
higher
level
onset
associ
increas
risk
death
day
posthct
hazard
ratio
hr
p
moder
associ
also
seen
epcr
hr
p
hr
p
figur
studi
demonstr
aid
diagnosi
ip
may
use
improv
discrimin
ip
respiratori
viral
pneumonia
addit
pcr
assay
differ
infecti
agent
importantli
patient
high
valu
day
posthct
high
risk
futur
ip
occurr
also
associ
higher
mortal
proteom
analysi
identifi
potenti
biomark
ip
could
function
diagnost
prognost
marker
ip
receptor
receptor
uniqu
ligand
recent
identifi
import
biomark
gvhd
also
appear
candid
marker
diagnosi
ip
compar
patient
uncompl
hct
studi
formal
comparison
patient
develop
gvhd
perform
discrimin
ip
viral
pneumonia
find
indic
may
marker
lung
injuri
support
previou
report
elev
level
acut
lung
injuri
play
role
protect
lung
injuri
interestingli
elev
earli
phase
hct
suggest
also
prognost
marker
futur
develop
ip
stronger
ppv
among
marker
elev
day
posthct
inflammatori
cytokin
shown
elev
patient
ip
similar
may
function
diagnost
marker
compar
unaffect
control
patient
viral
pneumonia
also
elev
earli
phase
hct
although
strong
ppv
multipl
analyt
model
combin
provid
best
model
fit
predict
ip
compar
control
diagnosi
day
posthct
howev
term
discrimin
auc
combin
model
increas
compar
model
use
suggest
test
second
biomark
might
worth
extra
cost
anoth
biomark
associ
ip
singl
best
marker
comparison
viral
pneumonia
diagnosi
ip
exclus
respiratori
viral
pneumonia
critic
sever
obstacl
bronchoscop
evalu
patient
poor
condit
avail
comprehens
assay
respiratori
virus
prevent
accur
diagnosi
ip
therefor
potenti
marker
help
distinguish
ip
viral
pneumonia
import
although
find
requir
valid
independ
cohort
etanercept
tnfr
inhibitor
use
treat
ip
decreas
level
report
patient
respond
etanercept
result
regard
predict
valu
potenti
clinic
relev
incid
ip
low
base
data
high
valu
day
posthct
identifi
subgroup
markedli
increas
likelihood
ip
occurr
would
allow
close
monitor
earli
posttransplant
biomarkerbas
preemptiv
intervent
enabl
person
medicin
target
popul
calcul
ppv
onset
pulmonari
symptom
show
high
ppv
approxim
provid
inform
chang
knowledg
priori
likelihood
ip
base
assum
preval
especi
patient
undergo
bronchoscop
examin
due
poor
condit
given
low
incid
ip
approxim
perform
weight
kaplanmei
estim
control
patient
ip
gener
repres
mortal
estim
found
associ
high
valu
increas
mortal
popul
typic
ip
preval
rate
prevent
lung
injuri
earli
phase
diseas
may
import
avoid
mortal
follow
ip
earli
monitor
posthct
could
inform
guid
preemptiv
therapi
prospect
trial
need
test
hypothesi
studi
strength
limit
cohort
constitut
one
largest
avail
cohort
patient
ip
patient
ip
viral
pneumonia
extrem
well
character
term
diagnost
panel
appli
first
time
biomark
studi
ip
posthct
predict
valu
rang
ip
preval
scenario
estim
provid
valuabl
practic
inform
regard
degre
knowledg
individu
biomark
valu
increas
understand
likelihood
ip
individu
especi
patient
undergo
bronchoscop
examin
diagnosi
ip
one
limit
studi
limit
number
ip
subject
due
low
incid
ip
avail
sampl
therefor
sampl
collect
long
time
period
might
affect
result
despit
multivari
analys
includ
key
clinic
variabl
moreov
number
subject
insuffici
evalu
result
within
strata
defin
presenc
absenc
acut
gvhd
instead
includ
acut
gvhd
clinic
variabl
multivari
analysi
second
limit
select
piv
hrv
case
repres
exampl
viral
pneumonia
chose
respiratori
virus
common
hct
recipi
associ
rel
high
rate
pneumonia
despit
high
incid
collect
databas
total
number
pneumonia
case
piv
hrv
sever
restrict
ie
time
point
posthct
copathogen
serum
avail
could
evalu
cytokin
profil
separ
viral
pneumonia
result
differ
pathogen
might
differ
cytokin
profil
therefor
might
biomark
distinguish
ip
viral
pneumonia
influenza
cmv
third
limit
lack
valid
cohort
establish
cohort
difficult
incid
rate
ip
low
center
identifi
ip
reliabl
biobank
sampl
patient
thu
independ
valid
cohort
optim
prospect
enrol
cohort
warrant
valid
find
conclus
identifi
potenti
biomark
help
screen
ip
use
marker
distinguish
ip
respiratori
viral
pneumonia
also
may
function
prognost
marker
futur
occurr
ip
studi
need
valid
find
determin
use
ip
candid
marker
author
thank
zachari
stednick
assist
retriev
clinic
data
jessica
yi
laurel
jonca
schronc
heather
andrew
jo
tono
assist
retriev
aliquot
sampl
specimen
provid
vaccin
infecti
diseas
divis
biospecimen
repositori
fred
hutch
financi
disclosur
work
partial
support
grant
nation
institut
health
sp
recipi
leukemia
lymphoma
societi
scholar
award
lilli
physician
scientist
initi
award
ss
recipi
joel
meyer
endow
scholarship
award
conflict
interest
statement
sp
patent
method
detect
graftversushost
diseas
licens
viracoribt
laboratori
author
conflict
interest
report
authorship
statement
ss
codesign
studi
collect
clinic
data
assist
data
interpret
wrote
manuscript
ju
perform
elisa
assay
ij
wl
perform
statist
analys
edit
manuscript
ts
provid
sampl
manag
edit
manuscript
jk
mh
perform
pcr
assay
edit
manuscript
kj
manag
pcr
assay
edit
manuscript
mb
codesign
studi
assist
data
interpret
wrote
manuscript
sp
codesign
studi
assist
data
interpret
wrote
manuscript
supplementari
data
relat
articl
found
onlin
